<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522557</url>
  </required_header>
  <id_info>
    <org_study_id>2020-KY-051</org_study_id>
    <nct_id>NCT04522557</nct_id>
  </id_info>
  <brief_title>Type I Interferon Alfa-2a in Postmastectomy Breast Reconstruction</brief_title>
  <official_title>Type I Interferon Alfa-2a in Postmastectomy Breast Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Implant-based reconstruction have become the most popular choices of&#xD;
      reconstruction for women undergoing breast mastectomy. Postoperative complications like&#xD;
      infection and tumor recurrence limit its application. Interferons (IFNs) are pleiotropic&#xD;
      cytokines that involve in immunoregulatory, anticancer and restricting infection. Especially,&#xD;
      type I IFN signaling is reported favourable for the success of conventional&#xD;
      chemotherapeutics, radiotherapy and immunotherapy. In addition, type I IFN can regulate the&#xD;
      activity of almost all immune cell types (including T cells, macrophages and innate&#xD;
      lymphocytes), creating a well-established immune environment to defense infectious and&#xD;
      relapsing disease. Implants are rapidly coated with extracellular matrix proteins and immune&#xD;
      protein components for the formation of a typical capsule. At the specific time point before&#xD;
      implantation, the locally utilized of IFN in intracavity breast is assumed to modify cellular&#xD;
      immune responses thus contributing to decreasing infection and tumor recurrence.&#xD;
&#xD;
      PURPOSE: This non-randomized phase I trial aims to explore dose range of IFNα-2a. Adverse&#xD;
      events are observed to assess drug safety and human tolerance index.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">July 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>Dose-limiting toxicity (DLT), defined as certain grade II toxicity such as nephrotoxicity and cardiotoxicity, grade III non-hematologic toxicity and grade IV hematologic toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal tolerable dose (MTD)</measure>
    <time_frame>7 days after surgery</time_frame>
    <description>Maximal tolerable dose (MTD), defined as a dose level where 2 or more subjects among 6 subjects suffering DLT. If the experiment reached the set maximum dose without any DLT occurring, the maximum dose was defined as MTD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>7 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Server adverse events (SAE)</measure>
    <time_frame>7 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Experimental: Participants with breast cancer enrolled in grou</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFNα-2a</intervention_name>
    <description>After mastectomy, it is used in the cavity of breast before conducting implantation.</description>
    <arm_group_label>Experimental: Participants with breast cancer enrolled in grou</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed the informed consent.&#xD;
&#xD;
          2. Female aged between 18 and 70 years.&#xD;
&#xD;
          3. Pathologically diagnosed operable breast cancer.&#xD;
&#xD;
          4. WHO Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          5. Newly diagnosed breast cancer.&#xD;
&#xD;
          6. The important organ functions meet the following criteria:&#xD;
&#xD;
               -  WBC &gt;=3.0 x 10^9/L; Neutrophilic granulocytes &gt;=1.5×10^9/L; Platelet &gt;=100 x&#xD;
                  10^9/L; Hb &gt;=9 g/dL;&#xD;
&#xD;
               -  Total bilirubin no more than 1.5 times the normal upper limit (ULN); AST and ALT&#xD;
                  no more than 1.5 times ULN; AKP no more than 2.5 times ULN;&#xD;
&#xD;
               -  Serum creatinine no more than 1.5 times ULN or Clearance rate of creatinine &gt;=&#xD;
                  60ml/min;&#xD;
&#xD;
               -  Thyroid stimulating hormone (TSH) &lt;= ULN (T3, T4 levels need to be detected&#xD;
                  simultaneously if abnormalities, the patient can be included if T3, T4 levels is&#xD;
                  normal);&#xD;
&#xD;
               -  LVEF basement &gt;= 50%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of distant metastasis.&#xD;
&#xD;
          2. Any contraindication of nipple-areolar complex (NAC) saving mastectomy (NSM):&#xD;
&#xD;
               -  Intraoperative biopsy revealed carcinoma invasion of NAC.&#xD;
&#xD;
               -  Paget's disease of breast.&#xD;
&#xD;
               -  Tumor distant from NAC less than 1 cm.&#xD;
&#xD;
          3. Any invasive malignancy diagnosed within previous 5 years (other than successfully&#xD;
             treated cervical carcinoma in situ, skin basal cell carcinoma or cutaneous squamous&#xD;
             cell carcinoma).&#xD;
&#xD;
          4. At least 4 months since prior interferon therapy.&#xD;
&#xD;
          5. At least 3 weeks since prior major surgery requiring general anesthesia.&#xD;
&#xD;
          6. At least 3 weeks since prior radiotherapy or chemotherapy.&#xD;
&#xD;
          7. Hypersensitivity to interferon or other components: urticaria, angioedema, bronchial&#xD;
             stenosis, anaphylaxis, or Stevens-Johnson syndrome.&#xD;
&#xD;
          8. Prior organ allograft.&#xD;
&#xD;
          9. Use of an unlicensed or other investigational drug within 4 weeks.&#xD;
&#xD;
         10. Any severe comorbidities, inability to give informed consent or unavailability for&#xD;
             follow-up, including but not limited to any of the following:&#xD;
&#xD;
               -  Heart failure above NYHA class 2 level; high-risk uncontrollable arrhythmia;&#xD;
                  unstable angina pectoris; myocardial infarction within 1 intervention.&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease requires treatment.&#xD;
&#xD;
               -  Chronic liver disease (cirrhosis, chronic active hepatitis, etc.).&#xD;
&#xD;
               -  Cerebrovascular accident occurred within 6 months.&#xD;
&#xD;
               -  Severe epilepsy or central nervous system diseases.&#xD;
&#xD;
               -  Hypertension which cannot be well controlled by antihypertensive drugs.&#xD;
&#xD;
               -  Abnormal coagulation, bleeding tendency, or receiving thrombolysis or&#xD;
                  anticoagulant therapy.&#xD;
&#xD;
               -  Chronic renal insufficiency.&#xD;
&#xD;
               -  Active infection.&#xD;
&#xD;
               -  Psychiatric disability, etc.&#xD;
&#xD;
         11. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shicheng Su, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shicheng Su, M.D.,Ph.D.</last_name>
    <phone>+86 13631304227</phone>
    <email>sushch@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shicheng Su</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shicheng Su, M.D., Ph.D.</last_name>
      <phone>+86 13631304227</phone>
      <email>sushch@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Shicheng Su</investigator_full_name>
    <investigator_title>Director of Shuhua Breast Cancer Research Center of Sun Yat- sen Memorial Hospital</investigator_title>
  </responsible_party>
  <keyword>Breast reconstruction</keyword>
  <keyword>Implants</keyword>
  <keyword>Interferon (IFN)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferon alpha-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

